SCHEMBL5543032

SCHEMBL5543032

O=[C]NCCc1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.56
MIF P14174 2/20 0.51
CNR1 P21554 1/20 0.50
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
ACP3 P15309 1/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
DAO P14920 2/20 0.47
IDO1 P14902 2/20 0.46
TDP1 Q9NUW8 1/20 0.45
HTR2A P28223 2/20 0.45
HTR2B P41595 2/20 0.45
HTR2C P28335 1/20 0.45
NR3C2 P08235 1/20 0.45
MAPT P10636 2/20 0.44
SIGMAR1 Q99720 2/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535926 0.91 TAAR1 (0.53) TAAR1MIFCNR1HDAC1HDAC8
SCHEMBL5540228 0.88 HDAC1 (0.53) TAAR1MIFCNR1HDAC1HDAC8
SCHEMBL3304999 0.83 MLYCD (0.51) TAAR1MIFHDAC1ACP3MEN1
Hydrochloric Acid SCHEMBL27770501 0.80 TAAR1 (0.62) TAAR1MIFCNR1HDAC1HDAC8
SCHEMBL5535468 0.80 TAAR1 (0.50) TAAR1MIFCNR1HDAC1HDAC8
SCHEMBL9482147 0.78 TAAR1 (0.61) TAAR1MIFCNR1HDAC1HDAC8
SCHEMBL28945212 0.78 TAAR1 (0.66) TAAR1MIFCNR1HDAC1HDAC8
SCHEMBL3920885 0.78 TAAR1 (0.61) TAAR1MIFCNR1KDM4EMEN1
SCHEMBL5541700 0.78 TAAR1 (0.61) TAAR1MIFHDAC1HDAC8ACP3
SCHEMBL5543041 0.77 TAAR1 (0.56) TAAR1MIFCNR1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TAAR1 364/4885MIF 1824/4885CNR1 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.